PUBLISHER: The Insight Partners | PRODUCT CODE: 1463640
PUBLISHER: The Insight Partners | PRODUCT CODE: 1463640
The South & Central America aortic valve replacement devices market is expected to grow from US$ 365.63 million in 2022 to US$ 876.41 million by 2030. It is estimated to grow at a CAGR of 11.5% from 2022 to 2030.
Advancements in Aortic Valve Replacement Devices Fuels South & Central America Aortic Valve Replacement Devices Market
The development of minimally invasive surgical techniques (MIS), such as transcatheter aortic valve replacement (TAVR), has modernized the treatment of aortic stenosis (AS). Transcatheter aortic valve replacement is less invasive than traditional open-heart surgery, making it possible for high-risk patients who may not have been eligible for surgery to receive treatment. Moreover, developments in materials and design have led to the development of stronger and biocompatible aortic valve replacements, which have improved patient outcomes and reduced the risk of complications.
A few technological advancements by the players in the aortic valve replacement devices are mentioned below:
In January 2023, Abbott received FDA approval for the Navitor transcatheter aortic valve implantation (TAVI) system to treat people with severe aortic stenosis at high risk of open-heart surgery. Navitor is the latest addition to the company's extensive transcatheter structural heart portfolio, which offers physicians and patients less invasive treatment options for a range of serious heart diseases.
In September 2021, Abbott received FDA approval for its Epic Plus and Epic Plus Supra Stented Tissue Valves to improve therapy options for people with aortic or mitral valve disease. With this new device, Abbott expanded its Epic surgical valve platform.
Therefore, technological advancements are creating lucrative opportunities in the aortic valve replacement devices market.
South & Central America Aortic Valve Replacement Devices Market Overview
The South & Central America aortic valve replacement devices market is segmented into Brazil, Argentina, and the Rest of South & Central America. The market in the region is expected to grow due to the surge in prevalence of aortic stenosis, initiatives undertaken by various government organizations to create awareness about valve replacement surgeries.
South & Central America Aortic Valve Replacement Devices Market Revenue and Forecast to 2030 (US$ Million)
South & Central America Aortic Valve Replacement Devices Market Segmentation
The South & Central America aortic valve replacement devices market is segmented into product, surgery, end user, and country.
Based on product, the South & Central America aortic valve replacement devices market is segmented into sutureless valve and mechanical valve. The sutureless valve held a larger South & Central America aortic valve replacement devices market share in 2022.
Based on surgery, the South & Central America aortic valve replacement devices market is segmented into minimally invasive surgery and open surgery. The minimally invasive surgery segment held a larger South & Central America aortic valve replacement devices market share in 2022.
Based on end user, the South & Central America aortic valve replacement devices market is segmented into hospitals & clinics, ambulatory surgical centers, and others. The hospitals & clinics segment held the largest South & Central America aortic valve replacement devices market share in 2022.
Based on country, the South & Central America aortic valve replacement devices market has been categorized into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America aortic valve replacement devices market share in 2022.
Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, LivaNova Plc, Edwards Lifesciences Corp, Braile Biomedica Industry, Commerce and Representations Ltd, Artivion Inc, Venus MedTech HangZhou Inc, and Labcor Laboratorios Ltda. , are some of the leading companies operating in the aortic valve replacement devices market.